Global Markets Direct’s, 'Lung Infections - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Lung Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Infections. Lung Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Lung Infections. - A review of the Lung Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Lung Infections pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Lung Infections. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Lung Infections pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents
Lung Infections - Pipeline Review, H2 2013 Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Lung Infections Overview 6 Therapeutics Development 7 An Overview of Pipeline Products for Lung Infections 7 Lung Infections Therapeutics under Development by Companies 9 Lung Infections Therapeutics under Investigation by Universities/Institutes 10 Late Stage Products 11 Comparative Analysis 11 Mid Clinical Stage Products 12 Comparative Analysis 12 Early Clinical Stage Products 13 Comparative Analysis 13 Pre-Clinical Stage Products 14 Comparative Analysis 14 Lung Infections Therapeutics - Products under Development by Companies 15 Lung Infections Therapeutics - Products under Investigation by Universities/Institutes 16 Companies Involved in Lung Infections Therapeutics Development 17 Targeted Genetics Corporation 17 Bayer AG 18 Insmed Incorporated 19 Creative Antibiotics Sweden AB 20 Destiny Pharma Ltd. 21 Lung Infections - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Route of Administration 23 Assessment by Molecule Type 25 Drug Profiles 27 amikacin - Drug Profile 27 Product Description 27 Mechanism of Action 27 RandD Progress 27 ciprofloxacin - Drug Profile 29 Product Description 29 Mechanism of Action 29 RandD Progress 29 amikacin liposomal - Drug Profile 31 Product Description 31 Mechanism of Action 31 RandD Progress 31 amikacin liposomal - Drug Profile 33 Product Description 33 Mechanism of Action 33 RandD Progress 33 BioPhage-PR - Drug Profile 35 Product Description 35 Mechanism of Action 35 RandD Progress 35 XF-70 - Drug Profile 36 Product Description 36 Mechanism of Action 36 RandD Progress 36 INP-11252 - Drug Profile 37 Product Description 37 Mechanism of Action 37 RandD Progress 37 Cystic Fibrosis Phage - Drug Profile 38 Product Description 38 Mechanism of Action 38 RandD Progress 38 Drug For Staphyloccal enterotoxin B And Toxic Shock Syndrome Toxin-1 - Drug Profile 39 Product Description 39 Mechanism of Action 39 RandD Progress 39 Lung Infections Therapeutics - Drug Profile Updates 40 Lung Infections Therapeutics - Discontinued Products 52 Lung Infections Therapeutics - Dormant Products 53 Lung Infections - Product Development Milestones 54 Featured News and Press Releases 54 May 14, 2013: Insmed Receives Key Composition Of Matter Patent Allowance For ARIKACE In Europe 54 Apr 17, 2013: KaloBios Pharma To Present Data On KB001-A At BIO 2013 International Convention 54 Mar 28, 2013: Insmed's Arikace Receives Orphan Drug Designation For Treating Infections Caused By Non- tuberculous Mycobacteria 55 Aug 02, 2012: Insmed Receives Second Composition Of Matter Patent For ARIKACE 55 Jun 27, 2012: Insmed Doses First Patient In TARGET-NTM Phase II Clinical Trial Of ARIKACE in Patients With Non-Tuberculous Mycobacteria Lung Disease 55 May 23, 2012: Insmed Begins Screening Patients For TARGET-NTM US Clinical Trial Of ARIKACE In Patients With Non-Tuberculous Mycobacterial Lung Disease 56 May 07, 2012: Insmed Announces Lifting Of Clinical Hold By FDA On ARIKACE In Cystic Fibrosis Patients With Pseudomonas Lung Infections 57 Sep 15, 2011: Nabriva Therapeutics Presents Extended Phase II Results For Pleuromutilin Antibiotic BC-3781 57 Appendix 59 Methodology 59 Coverage 59 Secondary Research 59 Primary Research 59 Expert Panel Validation 59 Contact Us 60 Disclaimer 60
List of Tables
Number of Products Under Development for Lung Infections, H2 2013 7 Products under Development for Lung Infections - Comparative Analysis, H2 2013 8 Number of Products under Development by Companies, H2 2013 9 Number of Products under Investigation by Universities/Institutes, H2 2013 10 Comparative Analysis by Late Stage Development, H2 2013 11 Comparative Analysis by Mid Clinical Stage Development, H2 2013 12 Comparative Analysis by Early Clinical Stage Development, H2 2013 13 Comparative Analysis by Pre-Clinical Stage Development, H2 2013 14 Products under Development by Companies, H2 2013 15 Products under Investigation by Universities/Institutes, H2 2013 16 Targeted Genetics Corporation, H2 2013 17 Bayer AG, H2 2013 18 Insmed Incorporated, H2 2013 19 Creative Antibiotics Sweden AB, H2 2013 20 Destiny Pharma Ltd., H2 2013 21 Assessment by Monotherapy Products, H2 2013 22 Assessment by Stage and Route of Administration, H2 2013 24 Assessment by Stage and Molecule Type, H2 2013 26 Lung Infections Therapeutics - Drug Profile Updates 40 Lung Infections Therapeutics - Discontinued Products 52 Lung Infections Therapeutics - Dormant Products 53
List of Figures
Number of Products under Development for Lung Infections, H2 2013 7 Products under Development for Lung Infections - Comparative Analysis, H2 2013 8 Products under Development by Companies, H2 2013 9 Products under Investigation by Universities/Institutes, H2 2013 10 Late Stage Products, H2 2013 11 Mid Clinical Stage Products, H2 2013 12 Early Clinical Stage Products, H2 2013 13 Pre-Clinical Stage Products, H2 2013 14 Assessment by Monotherapy Products, H2 2013 22 Assessment by Route of Administration, H2 2013 23 Assessment by Stage and Route of Administration, H2 2013 24 Assessment by Molecule Type, H2 2013 25 Assessment by Stage and Molecule Type, H2 2013 26